Core Viewpoint - Macquarie's research report anticipates a robust performance from JD Health in the third quarter, leading to a projected year-on-year revenue growth of 22% in the second half of the year [1] Group 1: Company Performance - JD Health is expected to maintain its position as a major distribution channel for healthcare products, further increasing market share and consolidating the market despite the diminishing impact of offline pharmacies [1] - The company is adopting a cautious strategy regarding the expansion of offline stores, which is reflected in its operational approach [1] Group 2: Financial Projections - For the second half of the year, adjusted net profit margin is projected to increase by 90 basis points year-on-year to 8.1%, with the corresponding adjusted net profit estimated at 2.9 billion yuan [1] - Macquarie has raised its target price for JD Health from 62.14 HKD to 74.57 HKD, corresponding to a forecasted price-to-earnings ratio of 30 times for the next year, while maintaining an "outperform" rating [1]

Core Viewpoint - Macquarie has raised the target price for JD Health (06618) by 20%, from HKD 62.14 to HKD 74.57, while maintaining an "Outperform" investment rating [1] Group 1: Financial Projections - Macquarie expects JD Health to achieve a 22% year-on-year revenue growth in the second half of 2025, driven by a positive trend in the third quarter [1] - The adjusted net profit margin for the second half is projected to reach 8.1%, reflecting a year-on-year increase of 90 basis points [1] Group 2: Market Position and Strategy - The company is anticipated to strengthen its position in key healthcare product distribution channels, particularly in light of weak performance in offline pharmacies [1] - Macquarie believes that the company's cautious approach to offline store expansion and increased spending during the fourth quarter promotional period will support its market share growth [1] Group 3: Revenue and Profitability Drivers - The growth momentum in the second half is expected to be bolstered by the direct launch of more new drugs and stronger advertising spending from merchants [1] - An increase in drug sales is expected to enhance overall gross margin, with a projected year-on-year expansion of 1.5 percentage points to 23.7% in the second half [1]

Core Viewpoint - Macquarie has raised the target price for JD Health (06618) by 20%, from HKD 62.14 to HKD 74.57, while maintaining an "Outperform" rating. The earnings forecast for the company remains unchanged [1]. Group 1: Revenue Growth and Market Position - JD Health is expected to achieve a 22% year-on-year revenue growth in the second half of 2025, driven by a strong trend in the third quarter [1]. - The company is anticipated to solidify its position in key healthcare product distribution channels, enhancing market share and market integration despite weak performance in offline pharmacies [1]. Group 2: Profitability and Margin Expectations - The company is projected to maintain strong growth momentum in the second half, benefiting from the direct launch of new drugs and increased advertising spending from merchants [1]. - An increase in drug sales is expected to positively impact overall gross margin, with a projected year-on-year expansion of 1.5 percentage points to 23.7% in the second half [1]. - Adjusted net profit margin is expected to reach 8.1% in the second half, reflecting a year-on-year increase of 90 basis points, considering cautious expansion in offline stores and increased spending during the fourth quarter promotional period [1].